Tempest Q3 2022 net loss $8.9M; cash at $42.8M; pipeline milestones on track

Tempest Therapeutics, Inc.

2022-Q3 EPS reported -$2.46

Cash and equivalents $42.8M as of Sep 30, 2022, down from $51.8M at Dec 31, 2021.
Net loss Q3 2022 of $8.9M ($0.66/sh) vs $8.1M ($1.21/sh) in Q3 2021.
R&D expense increased to $6.0M from $4.6M on expanded R&D efforts.
TPST-1120 Phase 1b/2 HCC study with Roche; early data from first 40 patients expected H1 2023.
TPST-1495 Phase 1 dose optimization data expected by year-end or early 2023.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Tempest Therapeutics, Inc. reported the third fiscal quarter ended September 30, 2022 results: net income $8.9 million, EPS $0.66.

Period: the third fiscal quarter ended September 30, 2022
Net income: $8.9 million
EPS: $0.66
Result: reported results

Exact text from the filing

Net loss and net loss per share for the third quarter of 2022 were $8.9 million and $0.66, respectively

View on SEC.gov

49 earnings releases filed in the last 30 days. Browse all earnings releases →

Tempest Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001544227-22-000004

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.